Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Avalo Therapeutics Inc
(NQ:
AVTX
)
9.000
-0.030 (-0.33%)
Streaming Delayed Price
Updated: 9:59 AM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Avalo Therapeutics Inc
< Previous
1
2
Next >
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 08, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Participation in September Investor Conferences
September 04, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 09, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
June 24, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports 2023 Financial Results and Provides Business Updates
March 29, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
December 27, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
December 07, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics
September 27, 2023
NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks...
Via
TheNewswire.com
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
September 26, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Enters into Agreement to Divest AVTX-800 Series
September 12, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Participate in SVB Securities Therapeutics Forum
July 06, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
June 26, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 22, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 15, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports 2022 Financial Results and Provides Business Updates
March 29, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
March 07, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
February 02, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
February 02, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.